IN8bio, Inc. - $INAB STOCK NEWS

IN8bio presented details about its robust and reproducible gamma-delta T cell therapy manufacturing platform at ASGCT 2024. The data demonstrate significant advancements in the characterization of gamma-delta T cell-based therapies, showing increased potency, effector functions, and trafficking capabilities. The study evaluated T cell products from healthy donors and GBM patients, revealing consistent profiles and gene expression changes throughout the manufacturing process.

IN8bio, Inc. (Nasdaq: INAB) reported financial results for Q1 2024, highlighting progress in gamma-delta T cell programs. Key points include preclinical data on nsCAR platform targeting cancer cells, peer-reviewed publication on DeltEx Drug Resistant Immunotherapy for GBM, and dosing first patient in Phase 2 clinical trial. Financially, R&D expenses increased to $4.9 million, G&A expenses were $3.7 million, net loss was $8.6 million, and cash position stood at $13.0 million.

IN8bio, Inc. (Nasdaq: INAB) has dosed the first patient in a Phase 2 clinical trial of INB-400 for newly diagnosed glioblastoma multiforme (GBM). INB-400 is an autologous gamma-delta T cell therapy genetically engineered to survive chemotherapy and enhance cancer cell killing. The trial, expected to enroll up to 40 patients, aims to evaluate safety, tolerability, and overall survival rate at 12 months. INB-400 was granted Orphan Drug Designation in 2023 and is designed to work alongside standard-of-care treatments like temozolomide.

IN8bio, Inc. (Nasdaq: INAB) will present on Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product at the ASGCT 2024 Annual Meeting. The presentation focuses on novel production platforms and will take place on May 10th, 2024, in Baltimore, MD. The data will be available online post-presentation.

IN8bio, Inc. (INAB) to present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. CEO William Ho to discuss innovative gamma-delta T cell therapies. One-on-one meetings available for investors. Webcast to be archived for 90 days.

IN8bio, Inc. (Nasdaq: INAB) announced promising preclinical data on its nsCAR platform, INB-300, showing improved selectivity in targeting leukemia cells while sparing healthy tissue. The technology aims to prevent off-target effects common in CAR-T therapies, potentially expanding treatment options for myeloid malignancies and solid tumors. Results presented at AACR 2024 revealed enhanced tumor killing capabilities without significant harm to healthy cells, indicating a 5.5x increase in selectivity. IN8bio plans to optimize the platform further for safer and more effective cancer treatments.

IN8bio, Inc. (INAB) reported positive results from Phase 1 studies of INB-100 in leukemia and INB-200 in GBM, showcasing durable remissions and extended progression-free survival. The company closed a private placement, securing $14.4 million in gross proceeds, strengthening its financial position. Dr. Corinne Epperly joined the Board of Directors. IN8bio highlighted upcoming pipeline milestones and events, including Phase 2 studies and potential IND applications. Financially, R&D expenses increased due to program advancements, while G&A expenses decreased. The company reported a net loss of $7.6 million for Q4 2023 and had a cash position of $21.3 million as of December 31, 2023.

IN8bio, Inc. (INAB) presents new preclinical data on its non-signaling gamma-delta T cell CAR platform targeting CD-33 and CD-123 at the AACR Annual Meeting. The platform shows promise in selectively targeting cancer cells while sparing healthy tissue, potentially addressing 'undruggable' tumor types.

IN8bio, Inc. (INAB) CEO to present at investor conferences in March, showcasing innovative gamma-delta T cell therapies. Webcast available on the company's website.